Literature DB >> 29312678

Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle.

Antonio Marchetti1, Alessia Di Lorito1, Fiamma Buttitta1.   

Abstract

Entities:  

Year:  2017        PMID： 29312678      PMCID： PMC5756957          DOI： 10.21037/jtd.2017.11.105

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  5 in total

1.  Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.

Authors:  Antonio Marchetti; Massimo Barberis; Renato Franco; Graziano De Luca; Maria Vittoria Pace; Stefania Staibano; Marco Volante; Fiamma Buttitta; Elena Guerini-Rocco; Luisella Righi; Tommaso D'antuono; Giorgio V Scagliotti; Carmine Pinto; Gaetano De Rosa; Mauro Papotti
Journal:  J Thorac Oncol       Date:  2017-08-14       Impact factor: 15.609

Review 2.  Engineering macrophages to eat cancer: from "marker of self" CD47 and phagocytosis to differentiation.

Authors:  Cory Alvey; Dennis E Discher
Journal:  J Leukoc Biol       Date:  2017-05-18       Impact factor: 4.962

3.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 4.  Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.

Authors:  Xiang Zheng; Kati Turkowski; Javier Mora; Bernhard Brüne; Werner Seeger; Andreas Weigert; Rajkumar Savai
Journal:  Oncotarget       Date:  2017-07-18

5.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962
  5 in total
  6 in total

Review 1.  Immune Checkpoints: Therapeutic Targets for Pituitary Tumors.

Authors:  Ding Nie; Yimeng Xue; Qiuyue Fang; Jianhua Cheng; Bin Li; Dawei Wang; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  Dis Markers       Date:  2021-08-16       Impact factor: 3.434

Review 2.  The Promises of Natural Killer Cell Therapy in Endometriosis.

Authors:  Janneke Hoogstad-van Evert; Romy Paap; Annemiek Nap; Renate van der Molen
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

3.  Malignant transformation of oral leukoplakia is associated with macrophage polarization.

Authors:  Manuel Weber; Falk Wehrhan; Christoph Baran; Abbas Agaimy; Maike Büttner-Herold; Hatice Öztürk; Kristina Neubauer; Claudia Wickenhauser; Marco Kesting; Jutta Ries
Journal:  J Transl Med       Date:  2020-01-07       Impact factor: 5.531

Review 4.  Inflammatory Response Mechanisms of the Dentine-Pulp Complex and the Periapical Tissues.

Authors:  Kerstin M Galler; Manuel Weber; Yüksel Korkmaz; Matthias Widbiller; Markus Feuerer
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

5.  Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.

Authors:  Mohamed A Ghonim; Salome V Ibba; Abdelmetalab F Tarhuni; Youssef Errami; Hanh H Luu; Matthew J Dean; Ali H El-Bahrawy; Dorota Wyczechowska; Ilyes A Benslimane; Luis Del Valle; Amir A Al-Khami; Augusto C Ochoa; A Hamid Boulares
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

6.  PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.

Authors:  John Turchini; Loretta Sioson; Adele Clarkson; Amy Sheen; Anthony J Gill
Journal:  Endocr Pathol       Date:  2021-03-11       Impact factor: 3.943
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.